Safety of Temporary Interruption of Antiplatelet Therapy in Dengue Fever with Thrombocytopenia

Dengue fever, caused by a flavivirus transmitted by Aedes mosquitoes, is endemic in more than 100 countries with 2.5 billion people at risk.1 With climate change and globalization causing geographical expansion of Aedes mosquitoes, increased exposure especially in dengue-na ïve populations is predicted.2,3 Thrombocytopenia commonly occurs with dengue 4 and may be associated with bleeding. Avoidance of intramuscular injections, bed rest and measures to reduce risk of falls are usually advised. Increasingly, dengue occurs in older adults,5–7 and adult patients with de ngue fever may have comorbidities such as ischemic heart disease with coronary artery stent insertion or ischemic stroke for which they are on long-term antiplatelet therapy.
Source: Journal of Infection - Category: Infectious Diseases Authors: Source Type: research